Li Zhang serves as the Senior Director of Preclinical Research at AffaMed Therapeutics, where he leverages his extensive expertise in pharmacology and neuroscience to drive innovative drug discovery and development initiatives. With a strong focus on target identification and validation, Li plays a pivotal role...
Li Zhang serves as the Senior Director of Preclinical Research at AffaMed Therapeutics, where he leverages his extensive expertise in pharmacology and neuroscience to drive innovative drug discovery and development initiatives. With a strong focus on target identification and validation, Li plays a pivotal role in advancing preclinical models that are crucial for understanding the pharmacokinetics and pharmacodynamics (PK/PD) of novel therapeutics. His current projects highlight his leadership in the clinical development of AM712, a biologic aimed at treating retinal vascular diseases, including neovascular age-related macular degeneration (nAMD). Under his guidance, the Phase 1 study is actively progressing in the US, where he is responsible for shaping the overall program strategy and ensuring meticulous execution of the study protocols.
In addition to his work on AM712, Li is also leading the preclinical development of a promising small molecule therapeutic. His proficiency in assay development—both in vitro and in vivo—enables him to create robust target engagement and biomarker assays that are critical for translating preclinical findings into clinical applications. His background in neuroanatomy and neuropharmacology, combined with his skills in translational biology and immunohistochemistry, positions him uniquely to bridge the gap between laboratory research and clinical outcomes. Li’s commitment to advancing the life sciences field is evident in his strategic approach to translational research, ensuring that innovative therapies are not only developed but also effectively brought to market to improve patient outcomes.
